Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Claggett

Showing results (171-180 of 361) with videos related to

Pageof 37
Sort By:
European Journal of Heart Failure|June 11, 2016
Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trialOrly Vardeny, Brian Claggett, Milton Packer, et al.
American Journal of Hypertension|September 10, 2015
Prehypertension is Associated With Abnormalities of Cardiac Structure and Function in the Atherosclerosis Risk in Communities StudyAngela B S Santos, Deepak K Gupta, Natalie A Bello, et al.
Circulation. Heart Failure|November 12, 2020
Cardiac Myosin Activator Omecamtiv Mecarbil Improves Left Ventricular Myocardial Deformation in Chronic Heart Failure: The COSMIC-HF TrialTor Biering-Sørensen, Masatoshi Minamisawa, Brian Claggett, et al.
Journal of the American Heart Association|March 7, 2022
Cardiac Structure and Function and Diabetes-Related Risk of Death or Heart Failure in Older AdultsRiccardo M Inciardi, Brian Claggett, Deepak K Gupta, et al.
JAMA Cardiology|July 21, 2016
Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection FractionThomas A Gaziano, Gregg C Fonarow, Brian Claggett, et al.
Journal of the American College of Cardiology|March 9, 2019
B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF TrialPeder Langeland Myhre, Muthiah Vaduganathan, Brian Claggett, et al.
Hypertension (Dallas, Tex. : 1979)|December 21, 2018
HFE H63D Polymorphism and the Risk for Systemic Hypertension, Myocardial Remodeling, and Adverse Cardiovascular Events in the ARIC StudySenthil Selvaraj, Sara Seidelmann, Odilson M Silvestre, et al.
Clinical Chemistry|September 14, 2022
Comparative Effect of Angiotensin Receptor Neprilysin Inhibition on B-type Natriuretic Peptide Levels Measured by Three Different Assays: The PROVE-HF StudyPeder L Myhre, Margaret F Prescott, Brian Claggett, et al.
European Journal of Heart Failure|June 26, 2026
Consistent Efficacy of Vutrisiran Across Sexes in Transthyretin Cardiac Amyloidosis: Evidence from the HELIOS-B TrialJosephine Mansell, Xiaowen Wang, Karola S Jering, et al.
Circulation. Heart Failure|April 9, 2016
Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection FractionAngela B S Santos, Gabriela Querejeta Roca, Brian Claggett, et al.
Pageof 37

Showing results (171-180 of 361) with videos related to

Sort By:
Pageof 37
European Journal of Heart Failure|June 11, 2016
Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trialOrly Vardeny, Brian Claggett, Milton Packer, et al.
American Journal of Hypertension|September 10, 2015
Prehypertension is Associated With Abnormalities of Cardiac Structure and Function in the Atherosclerosis Risk in Communities StudyAngela B S Santos, Deepak K Gupta, Natalie A Bello, et al.
Circulation. Heart Failure|November 12, 2020
Cardiac Myosin Activator Omecamtiv Mecarbil Improves Left Ventricular Myocardial Deformation in Chronic Heart Failure: The COSMIC-HF TrialTor Biering-Sørensen, Masatoshi Minamisawa, Brian Claggett, et al.
Journal of the American Heart Association|March 7, 2022
Cardiac Structure and Function and Diabetes-Related Risk of Death or Heart Failure in Older AdultsRiccardo M Inciardi, Brian Claggett, Deepak K Gupta, et al.
JAMA Cardiology|July 21, 2016
Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection FractionThomas A Gaziano, Gregg C Fonarow, Brian Claggett, et al.
Journal of the American College of Cardiology|March 9, 2019
B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF TrialPeder Langeland Myhre, Muthiah Vaduganathan, Brian Claggett, et al.
Hypertension (Dallas, Tex. : 1979)|December 21, 2018
HFE H63D Polymorphism and the Risk for Systemic Hypertension, Myocardial Remodeling, and Adverse Cardiovascular Events in the ARIC StudySenthil Selvaraj, Sara Seidelmann, Odilson M Silvestre, et al.
Clinical Chemistry|September 14, 2022
Comparative Effect of Angiotensin Receptor Neprilysin Inhibition on B-type Natriuretic Peptide Levels Measured by Three Different Assays: The PROVE-HF StudyPeder L Myhre, Margaret F Prescott, Brian Claggett, et al.
European Journal of Heart Failure|June 26, 2026
Consistent Efficacy of Vutrisiran Across Sexes in Transthyretin Cardiac Amyloidosis: Evidence from the HELIOS-B TrialJosephine Mansell, Xiaowen Wang, Karola S Jering, et al.
Circulation. Heart Failure|April 9, 2016
Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection FractionAngela B S Santos, Gabriela Querejeta Roca, Brian Claggett, et al.
Pageof 37